SEL-212
Selecta Biosciences
[]
we're excited that positive data from the phase 3 dissolve i &amp; ii trials of sel-212 in chronic refractory #gout will be featured at #eular23. the data underscore our belief in the immtor platform &amp; its potential to deliver meaningful tolerogenic therapies. 
We are a clinical-stage biotech company committed to overcoming immunogenicity using our pioneering ImmTOR platform.